BOOK A DEMO

Sonic Incytes Recognized at 2023 LSBC Awards Gala

Sonic Incytes was recognized as a “Company to Watch” at the 25th Annual LSBC Awards Gala, presented by Farris. This recognition underscores Sonic Incytes’ commitment to healthcare innovation and its groundbreaking product, Velacur, which is contributing to the fight against the global epidemic of non-alcoholic fatty liver disease—a condition that impacts nearly 30% of the world’s population. Sonic Incytes is poised for significant growth as the first NASH therapeutic potentially hits the market in the first quarter of 2024.

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.

Julia PinterMarketing Director

Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.